Read more

November 17, 2023
1 min watch
Save

VIDEO: Further study needed on bromodomain inhibitor in advanced sarcoma

Sandra D’Angelo, MD, talked about preliminary results from a phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumors in a video interview with Healio.

The study was presented at the Connective Tissue Oncology Society Annual Meeting.

“This clinical trial remains in progress at this time. We will see if further development occurs with this particular compound,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said.

Reference:

  • Livingston A, et al. Paper 25. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.